Serologicals subsidiary, Australian Stem Cell Centre sign agreement to commercialize stem cell products

By Lisa Kerner

Erie, Pa., April 21 - Serologicals Corp. and the Australian Stem Cell Centre have signed an agreement granting Serologicals' wholly owned subsidiary, Chemicon International, Inc., exclusive rights to commercialize, market and distribute stem cell reagents developed at the center.

Products available to researchers through Chemicon will initially include a novel and proprietary stem cell isolation kit and various proteins and antibodies, according to a company news release.

Chemicon will develop new research reagent products with assistance from the center, and other life science tools are expected to become part of the collaboration.

As part of the agreement, Chemicon will contribute funds, products and technical expertise to the new stem cell training program launched by the center, as well as make an in-kind contribution of research tools.

Chemicon, based in Temecula, Calif., provides a range of research products including specialty reagents, kits and antibodies.

Atlanta-based Serologicals develops and commercializes consumable biological products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.